Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to $14.4 million.

  • Capricor Therapeutics' Total Non-Current Liabilities rose 242.49% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 242.49%. This contributed to the annual value of $4.0 million for FY2024, which is 17.90% down from last year.
  • Per Capricor Therapeutics' latest filing, its Total Non-Current Liabilities stood at $14.4 million for Q3 2025, which was up 7,311.34% from $194,603 recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Total Non-Current Liabilities high stood at $26.0 million for Q1 2022, and its period low was $194,603 during Q2 2025.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $4.6 million (2024), whereas its average is $5.9 million.
  • Per our database at Business Quant, Capricor Therapeutics' Total Non-Current Liabilities spiked by 660.79% in 2022 and then tumbled by 95.60% in 2025.
  • Quarterly analysis of 5 years shows Capricor Therapeutics' Total Non-Current Liabilities stood at $5.8 million in 2021, then skyrocketed by 152.57% to $14.7 million in 2022, then plummeted by 66.97% to $4.9 million in 2023, then fell by 17.90% to $4.0 million in 2024, then spiked by 242.49% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, $194,603 for Q2 2025, and $3.8 million during Q1 2025.